劉 亞明

研究成果

每年研究成果 1997 2005 2009 2010 2012 2013 2014 2017 2020 2023

• 31 Article
• 12 Conference contribution
• 1 Review article

每年研究成果

每年研究成果

搜尋結果

• 2023

  Counterfactual Decomposition of Health Care Expenditures: From Cost-Based Payment to a Global Budget System

  Liu, Y. M., 2023 1月 1, 於: B.E. Journal of Economic Analysis and Policy. 23, 1, p. 79-111 33 p.

  研究成果: Article › 同行評審

  • Budget System 100%
  • Health Care Expenditures 86%
  • Decomposition 77%
  • Payment 50%
  • Prescription Drugs 42%

• Health care cost of floods: Evidence from Typhoon Morakot in Taiwan

  Liu, Y., Kuo, Y. L., Chu, H. J., Kuo, W. C. & Tseng, H. C., 2023 8月, 於: Journal of Asian Economics. 87, 101635.

  研究成果: Article › 同行評審

  • Health Care Costs 100%
  • Mental Illness 90%
  • Flooding 78%
  • Natural Disasters 73%
  • Taiwan 69%
• 2021

  Effect of air pollution on health care expenditure: Evidence from respiratory diseases

  Liu, Y. M. & Ao, C. K., 2021 4月, 於: Health Economics (United Kingdom). 30, 4, p. 858-875 18 p.

  研究成果: Article › 同行評審

  • Health Expenditures 87%
  • expenditures 76%
  • air 68%
  • health care 61%
  • Delivery of Health Care 52%
  20 引文 斯高帕斯（Scopus）
• 2020

  Population Aging, Technological Innovation, and the Growth of Health Expenditure: Evidence From Patients With Type 2 Diabetes in Taiwan

  Liu, Y. M., 2020 5月, 於: Value in Health Regional Issues. 21, p. 120-126 7 p.

  研究成果: Article › 同行評審

  開啟存取

  • Patient with Type 2 Diabetes 100%
  • Population Aging 60%
  • Health Expenditures 56%
  • technical innovation 52%
  • chronic illness 49%
  7 引文 斯高帕斯（Scopus）

• Revisiting the pharmaceutical price gap

  Liu, Y. M., 2020 2月, 於: Taiwan Journal of Public Health. 39, 1, p. 64-73 10 p.

  研究成果: Article › 同行評審

  • brand name 100%
  • pharmaceutical 90%
  • profit 83%
  • Names 69%
  • Generic Drugs 66%

• Understanding profit margins of medical providers from prescription drugs: Evidence from Taiwan

  Liu, Y. M., 2020, 於: International Health. 12, 4, p. 272-280 9 p.

  研究成果: Article › 同行評審

  開啟存取

  • Prescription Drugs 100%
  • profit 72%
  • medication 72%
  • Taiwan 71%
  • drug 57%
  4 引文 斯高帕斯（Scopus）

• 再論藥價差

  Liu, Y., 2020 2月 26, 於: Chinese Journal of Public Health. 39, 1, p. 64-73

  研究成果: Article › 同行評審

  • brand name 100%
  • pharmaceutical 90%
  • profit 83%
  • Names 69%
  • Generic Drugs 66%
• 2017

  An empirical analysis of exits from the hospital market

  Liu, Y. M., Lo, T. F. & Nien, Y. T., 2017 6月, 於: Taiwan Journal of Public Health. 36, 3, p. 273-286 14 p.

  研究成果: Article › 同行評審

  • Budgets 100%
  • market 88%
  • budget 62%
  • Industry 48%
  • Ownership 41%
  2 引文 斯高帕斯（Scopus）

• Exploring the relationship between nursing hours per patient day and mortality rate of hospitalised patients in Taiwan

  Chang, Y. C., Yen, M., Chang, S. M. & Liu, Y. M., 2017 3月 1, 於: Journal of Nursing Management. 25, 2, p. 85-92 8 p.

  研究成果: Article › 同行評審

  開啟存取

  • Nursing 84%
  • Mortality 50%
  • Epidemiologic Confounding Factors 23%
  • Nurses 14%
  • Health Care Outcome Assessment 13%
  7 引文 斯高帕斯（Scopus）

• Recent trends in the use of antidiabetic medications from 2008 to 2013: A nation-wide population-based study from Taiwan

  Ou, H. T., Chang, K. C., Liu, Y. M. & Wu, J. S., 2017 3月 1, 於: Journal of Diabetes. 9, 3, p. 256-266 11 p.

  研究成果: Article › 同行評審

  • Hypoglycemic Agents 96%
  • Dipeptidyl-Peptidase IV Inhibitors 66%
  • Population 39%
  • Delivery of Health Care 18%
  • Pharmaceutical Preparations 12%
  22 引文 斯高帕斯（Scopus）
• 2016

  Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan

  Ou, H. T., Chen, Y. T., Liu, Y. M. & Wu, J. S., 2016 6月 1, 於: Diabetes Research and Clinical Practice. 116, p. 14-25 12 p.

  研究成果: Article › 同行評審

  • Metformin 100%
  • Cost-Benefit Analysis 80%
  • Cardiovascular Diseases 67%
  • Population 36%
  • Thiazolidinediones 24%
  10 引文 斯高帕斯（Scopus）
• 2014

  Choice of generic versus brand-name antidepressants in a regulated prescription drug market: evidence from Taiwan

  Liu, Y., Ou, H-T. & Yang, Y-K., 2014 12月 1, 於: The journal of mental health policy and economics. 17, 4, p. 163-172 10 p.

  研究成果: Article › 同行評審

  • brand name 100%
  • Prescription Drugs 85%
  • Names 69%
  • Antidepressive Agents 65%
  • medication 62%
  2 引文 斯高帕斯（Scopus）
• 2013

  Aged-related patterns of income-related inequality in mortality among the middle-aged and the elderly in Taiwan by different cohorts

  Lee, M. C. & Liu, Y. A. M., 2013 6月, 於: Taiwan Journal of Public Health. 32, 3, p. 279-288 10 p.

  研究成果: Article › 同行評審

  • mortality 84%
  • Taiwan 84%
  • Income 83%
  • Elderly 68%
  • income 67%

• Endogenous technological change in medicine and its impact on healthcare costs: Evidence from the pharmaceutical market in Taiwan

  Hsieh, C. R., Liu, Y. M. & Chang, C. L., 2013 4月, 於: European Journal of Health Economics. 14, 2, p. 287-295 9 p.

  研究成果: Article › 同行評審

  • Endogenous Technological Change 100%
  • pharmaceutical market 99%
  • Pharmaceutical Market 84%
  • Health Expenditures 75%
  • Health Care Costs 73%
  5 引文 斯高帕斯（Scopus）

• Endogenous Technological Change in Medicine and Its Impact on Health Care Costs: Evidence from the Pharmaceutical Market in Taiwan

  Liu, Y., Hsieh, C. R. & Chang, C. L., 2013 4月, 於: European Journal of Health Economics. 14, 2, p. 287-295

  研究成果: Article › 同行評審

• 台灣中高齡人口不同世代所得相關死亡率不平等之年齡變化趨勢

  Liu, Y. & 李妙純, 2013 5月, 於: 台灣公共衛生雜誌. 32, 3, p. 279-288

  研究成果: Article › 同行評審
• 2012

  Availability, health-care costs, and utilization patterns of biologics in Taiwan

  Hsieh, C. R. & Liu, Y. M., 2012 1月, 於: Value in Health. 15, 1 SUPPL., p. S35-S42

  研究成果: Article › 同行評審

  開啟存取

  • Patient Acceptance of Health Care 100%
  • Biological Products 82%
  • Health Care Costs 75%
  • Taiwan 70%
  • utilization 67%
  6 引文 斯高帕斯（Scopus）

• Availability, Healthcare Costs and Utilization Patterns of Biologics in Taiwan

  Liu, Y. & Hsieh, C. R., 2012, 於: Value in Health. 15, 1, p. 35-42

  研究成果: Article › 同行評審

• Determinants of generic entry in the regulated Taiwanese prescription drug market

  Liu, Y. & Cheng, J. S., 2012 12月 1, 於: Health Policy. 108, 2-3, p. 228-235 8 p.

  研究成果: Article › 同行評審

  • Prescription Drugs 100%
  • medication 72%
  • drug 57%
  • market 47%
  • market share 35%
  2 引文 斯高帕斯（Scopus）

• New drugs and the growth of health expenditure: Evidence from diabetic patients in Taiwan

  Liu, Y. M. & Hsieh, C. R., 2012 5月, 於: Health Economics. 21, 5, p. 496-513 18 p.

  研究成果: Article › 同行評審

  • Health Expenditures 100%
  • expenditures 86%
  • Taiwan 82%
  • drug 66%
  • Growth 49%
  9 引文 斯高帕斯（Scopus）

• Regulation and competition in the Taiwanese pharmaceutical market under national health insurance

  Liu, Y. M., Yang, Y. H. K. & Hsieh, C. R., 2012 5月, 於: Journal of Health Economics. 31, 3, p. 471-483 13 p.

  研究成果: Article › 同行評審

  • pharmaceutical market 100%
  • health insurance 69%
  • pharmaceutical 46%
  • profit 43%
  • regulation 39%
  15 引文 斯高帕斯（Scopus）
• 2011

  The determinants of the adoption of pharmaceutical innovation: Evidence from Taiwan

  Liu, Y. M., Kao Yang, Y. H. & Hsieh, C. R., 2011 3月, 於: Social Science and Medicine. 72, 6, p. 919-927 9 p.

  研究成果: Article › 同行評審

  • pharmaceutical 93%
  • Taiwan 84%
  • Pharmaceuticals 83%
  • Drugs 83%
  • Innovation 75%
  19 引文 斯高帕斯（Scopus）
• 2010

  Exploring the Income Effect from Health Insurance: Evidence from in Taiwan

  Liu, Y., 2010, 於: The Empirical Economics Letters, (JEL, Econlit). 9, 8

  研究成果: Article › 同行評審

• Hospital Competition and Prescribing Behaviors–Empirical Evidence from Taiwan

  Liu, Y., Yang, YH. K. & Ou, H-T., 2010, 於: Journal of Developing Areas. 43, 2, p. 125-141

  研究成果: Article › 同行評審
• 2009

  Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan

  Liu, Y. M., Yang, Y. H. K. & Hsieh, C. R., 2009 3月, 於: Journal of Health Economics. 28, 2, p. 341-349 9 p.

  研究成果: Article › 同行評審

  • Generic Drugs 100%
  • brand name 99%
  • Names 68%
  • medication 62%
  • Taiwan 60%
  74 引文 斯高帕斯（Scopus）

• The impact of brand equity on brand preference and purchase intentions in the service industries

  Chang, H. H. & Liu, Y. M., 2009, 於: Service Industries Journal. 29, 12, p. 1687-1706 20 p.

  研究成果: Article › 同行評審

  • Service industry 100%
  • Brand Preference 95%
  • Brand Equity 77%
  • Purchase Intention 67%
  • Service Industries 65%
  184 引文 斯高帕斯（Scopus）
• 2008

  健保新藥的使用與高血壓患者醫療支出的關係：以「血管張力素受體阻斷剤」為例

  Liu, Y., 2008, 於: 健康保險期刊. 4, 2, p. 31-47

  研究成果: Article › 同行評審
• 2007

  Hospital Competition under Global Budgets: Evidence from Diabetes Outpatient Treatments in Taiwan

  Liu, Y., 2007, 於: The Empirical Economics Letters, (JEL, Econlit). 4, 2, p. 46-52

  研究成果: Article › 同行評審
• 2005

  The effect of competition on the practice of outpatient services for diabetes patients at different levels of hospitals in Taiwan

  Liu, Y. M. & Kinsey, J., 2005 7月 10, 於: Applied Economics. 37, 12, p. 1411-1422 12 p.

  研究成果: Article › 同行評審

  • Diabetes 100%
  • Outpatient 90%
  • Taiwan 61%
  • Instrumental Variables 17%
  • Endogeneity 17%
  3 引文 斯高帕斯（Scopus）
• 2004

  An application of adverse selection: Rural agricultural production in China since the 1950s

  Liu, Y. M., 2004 11月 15, 於: Applied Economics Letters. 11, 14, p. 915-917 3 p.

  研究成果: Article › 同行評審

  • Adverse Selection 100%
  • Agricultural Production 96%
  • Rural Reform 78%
  • Pooling 52%
  • China 48%
• 1997

  大陸鄉鎮企業的產權結構分析

  Liu, Y., 1997 8月, 於: 中國大陸研究 ＝ Mainland China Studies (TSSCI). 40, 8, p. 71-81

  研究成果: Article › 同行評審